Healios K.K.

OTCPK:HLOS.F Stock Report

Market Cap: US$97.4m

Healios K.K Past Earnings Performance

Past criteria checks 0/6

Healios K.K has been growing earnings at an average annual rate of 2.3%, while the Biotechs industry saw earnings growing at 22.1% annually. Revenues have been growing at an average rate of 89.3% per year.

Key information

2.3%

Earnings growth rate

15.3%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate89.3%
Return on equity-357.2%
Net Margin-1,133.3%
Next Earnings Update14 Feb 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Healios K.K makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OTCPK:HLOS.F Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24549-6,2221,2492,247
30 Jun 24521-5,3891,2032,376
31 Mar 24124-5,5151,1432,443
31 Dec 23121-3,8231,1162,304
30 Sep 23174-3,3051,1622,312
30 Jun 23176-3,3011,2442,519
31 Mar 2386-4,4411,3743,265
31 Dec 2290-5,1691,3783,808
30 Sep 2241-5,1721,3924,169
30 Jun 2243-6,2781,4674,495
31 Mar 2243-5,3411,4283,946
31 Dec 2141-4,9101,6493,700
30 Sep 2136-5,1921,5803,500
30 Jun 2133-4,7961,4943,230
31 Mar 2129-5,2781,4373,175
31 Dec 2027-5,5121,1552,986
31 Dec 14279-4808040

Quality Earnings: HLOS.F is currently unprofitable.

Growing Profit Margin: HLOS.F is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: HLOS.F is unprofitable, but has reduced losses over the past 5 years at a rate of 2.3% per year.

Accelerating Growth: Unable to compare HLOS.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HLOS.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).

Return on Equity

High ROE: HLOS.F has a negative Return on Equity (-357.22%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 21:47
End of Day Share Price 2024/12/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Healios K.K. is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hidemaru YamaguchiCitigroup Inc
Akinori UedaGoldman Sachs
Miyabi YamakitaJefferies LLC